1.	Study of Ad.p53 DC Vaccine and 1-MTin Metastatic Invasive Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-16025, IRB 108255, NCI Protocol 8461, NCT01042535
2.	Phase II Study of Sipuleucel-T and 1-MT for Patients With Refractory Metastatic Prostate Cancer Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 2011LS109, NCT01560923
3.	1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000576700, MCC-15267, MCC-FL065, 15267, 8045, NCT00567931
4.	Phase I Study of 1-Methyl-D-Tryptophan and Docetaxel in Patients With Metastatic Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: MCC-16264, MCC-16264, 8784, NCT01191216
5.	Pilot Study of Carbon C 11 alpha-Methyltryptophan Positron-Emission Tomography Functional Imaging in Patients With Metastatic Invasive Breast Cancer Treated With 1-Methyl-D-Tryptophan Plus the Adenovirus-p53 Transduced Dendritic Cell Vaccine Phase: No phase specified Type: Diagnostic, Treatment Status: Approved-not yet active Age: 18 and older Sponsor: NCI Protocol IDs: MCC-16216, MCC-16216, 8701, NCT01302821